The New York Times – Business:
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
This post first appeared in The New York Times – Business. Read the original article.
The New York Times – Business:
GSK, which developed and sold versions of the now-discontinued blockbuster heartburn drug, agreed to pay up to $2.2 billion.
This post first appeared in The New York Times – Business. Read the original article.